Alzheimer’s Current Studies

Are you or a loved one experiencing memory problems? A new clinical trial may be right for you.

Help us learn more about an investigational drug for early Alzheimer’s disease by participating in a clinical trial.

WHO IS ELIGIBLE TO PARTICIPATE?

Study participants must*

• Be between 50 and 90 years old
• Be experiencing memory loss or have a current diagnosis of:
• Mild cognitive impairment or
• Mild dementia due to Alzheimer’s disease
• Have a study partner (such as a spouse, family member, or friend) who can attend study visits

Do you have a loved one with agitation associated with Alzheimer's dementia? Is their agitation becoming overwhelming?

To be eligible for this study, a potential participant must:

• Be between the ages of 50 and 90
• Have a diagnosis of probable Alzheimer’s disease
• Have moderate-to-severe agitation that interferes with their daily life

Additionally, potential participants must have a caregiver who spends a minimum of 2 hours per day, 4 days per week with them and is willing and able to comply with all study procedures.

What does the HOPE study for Alzheimer's disease involve?



If you are eligible and choose to enroll in the HOPE Study, you will:

• Use a non-invasive wearable study device at home daily for approximately 12 months
• Participate in study-related visits at clinical sites with experienced healthcare professionals in the presence of a study partner, such as a family member or friend
• Receive compensation for study-related expenses (such as travel) and time, for both the participant and study partner

Who can participate in the HOPE Study?

• People between 50 and 85 years of age
• Have a reliable study partner
• Meet other criteria which will be evaluated.

The ASCENT clinical trials are seeking participants aged 55 to 85 with mild Alzheimer's disease to understand the safety of an investigational drug called PRX012.



• Compensation will be provided for clinical trial participation
• Clinical trial related travel reimbursements may be provided
• No health insurance is needed

Learn more about the HARBOR research study of an investigational drug for adults who are showing signs of early Alzheimer’s disease or have been diagnosed with early Alzheimer’s.

To pre-qualify for this study, you must: 

• Be 50 to 90 years of age 
• Have shown signs of early Alzheimer’s or have been diagnosed with early Alzheimer’s

Apheleia is a pre-screener study that will use demographic information such as sex, age, race and ethnicity, medical history, memory assessments, and a blood draw to help identify people who may have markers or biological signs of Alzheimer’s disease.

This study is seeking 3,000 volunteers of all races, ethnicities, and backgrounds who:

• Are 50 to 90 years old
• Are experiencing trouble with their memory
• Have someone who can participate with them as a study partner

The BenfoTeam Trial

A new approach for treating early Alzheimer’s disease.

Basic eligibility criteria:

• Aged 50-89
• Living in the community
• Willing to participate in the BenfoTeam study for up to 18 months



Other criteria will apply.